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PLASMA RICH IN GROWTH FACTORS (PRGF-ENDORET) IN THE
TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS:
A RANDOMIZED CLINICAL TRIAL
M. Sánchez 1, E. Anitua 2, N. Fiz 1, J. Azofra 1, J. Usabiaga 3, E. Albillos 3,
A. Garcia 3, J. Albillos 4, R. Garate 4, A. JJ 5, S. Padilla 2, G. Orive 2. 1UCA,
Vitoria, Spain; 2BTI Biotechnology Inst. ImasD, S.L. C/ Jacinto Quincoces, 39
01007 Vitoria (Spain)., Vitoria, Spain; 3Hosp. Donostia. Paseo Doctor
Begiristain 115. San Sebastián- Donostia (Spain)., San Sebastian, Spain;
4 Policlínica Guipúzcoa. Paseo Miramón 174. San Sebastián- Donostia
(Spain)., San Sebastian, Spain; 5 bti Biotechnology Inst. ImasD, S.L. C/
Jacinto Quincoces, 39 01007 Vitoria (Spain)., Vitoria, Spain
Purpose: This multicenter, double-blind, hyaluronic acid-controlled clin-
ical trial evaluated the efﬁcacy and safety of PRGF-Endoret, an autologous
biological therapy for regenerative purposes, as a treatment for knee pain
from osteoarthritis.
Methods: We randomly assigned 176 patients with symptomatic knee
osteoarthritis to receive inﬁltrations with PRGF-Endoret or with hyaluronic
acid (three injections on a weekly basis). The primary outcome measure
was a 50 percent decrease in knee pain from baseline to week 24. We also
assessed pain, stiffness, and physical function using theWOMAC Index; the
rate of response using the criteria of the OMERACT-OARSI; and safety.
Results: The mean age of the patients was 59.8 years, and 52 percent were
women. As compared with the rate of response to hyaluronic acid, the rate
of response to PRGF-Endoret was 14.1 percentage points higher (P¼0.044).
Regarding the secondary outcome measures, the rate of response to PRGF-Endoret was in all the cases higher, although no signiﬁcant differences
were reached. For patients with moderate to severe pain at baseline, the
rate of response to PRGF-Endoret was 26 percentage points higher
(P¼0.086) than the rate of response to hyaluronic acid, although no
signiﬁcant differences were reached. Adverse events were mild and evenly
distributed among the groups.
Conclusions:PRGF-Endoret has both a faster time to response and more
enduring beneﬁcial effect than hyaluronic acid. Treatment with PRGF-
Endoret resulted in clinically signiﬁcant reductions in knee pain, stiffness
and physical function, with mild adverse effects, in patients with knee
osteoarthritis. (ClinicalTrials.gov number, NCT00782197).
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A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND
FEASIBILITY STUDY TO EVALUATE THE SAFETY AND PERFORMANCE
OF HYDROS JOINT THERAPY AND HYDROS-TA JOINT THERAPY FOR
MANAGEMENT OF PAIN ASSOCIATED WITH OSTEOARTHRITIS IN THE
KNEE
R.J. Petrella 1,2, P. Eamans 3, J. Alleyne 4,5, M. Maroney 6. 1U Western Ontario,
London, ON, Canada; 2 Lawson Hlth.Res. Inst., London, ON, Canada;
3Maastricht Univ. Med. Ctr., Maastricht, Netherlands; 4Univ. of Toronto,
Toronto, ON, Canada; 5Women's Coll. Hosp., Toronto, ON, Canada;
6Carbylan BioSurgery, Palo Alto, CA
Purpose: Carbylan Osteoarthritis Research 1.0 (COR 1.0) was a prospective,
multicenter, randomized, double-blind feasibility study to evaluate the
safety and performance of Hydros Joint Therapy (Hydros) and Hydros-TA
Joint Therapy (Hydros-TA) in subjects with Kellgren&Lawrence grade 2 and
3 osteoarthritis (OA) of the knee.
Methods: A total of 98 subjects were enrolled, treated, and followed for six
months post-treatment. Subjects were randomized 1:1:1 to Hydros (PEG
cross linked HA without TA), Hydros-TA (PEG cross linked HA with TA), or
Synvisc-One Hylan G-F 20 (Synvisc-One).
Hydros is a bioresorbable hyaluronan-based hydrogel suspended in
a hyaluronan solution. Hydros-TA incorporates a low dose (10mg) corti-
costeroid, triamcinolone acetonide, suspended within the hyaluronan
hydrogel, and is designed to retain steroid locally in the joint.
All randomized subjects received one 6 mL intra-articular (IA) injection in
the treatment knee by an unblinded injecting physician. The treatment
knee was the knee that met the inclusion criteria on the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) A (pain)
subscale score (50-90mm on 100mm VAS). Subjects and evaluating
physicians who followed subjects post-treatment were blinded to
treatment.
Subjects were seen by a treatment-blinded evaluating physician for post-
treatment follow-up at 2 weeks, 6 weeks, 13 weeks, and 26 weeks.
Subjective symptom rating and physical assessment including the full
WOMAC questionnaire were obtained at screening and each follow-up
visit. Subject global assessment was obtained at 13 weeks and subject and
physician global assessments were obtained at 26 weeks. Adverse events
were solicited at all visits.
The primary efﬁcacy endpoint was the time-weighted change from base-
line in the WOMAC A (pain) subscale average score for the treatment knee
over 26 weeks. Differences between treatment were assessed using an
analysis of covariance (ANCOVA) model.
Results: For the primary outcome, Hydros demonstrated a 41.2mm
reduction, Hydros-TA demonstrated a 42.2mm reduction and Synvisc-One
demonstrated a 37.5mm reduction from baseline pain. These results rep-
resented an improvement of 3.7mm and 4.7mm over Synvisc-One for
Hydros and Hydros-TA respectively. Greater reductions in pain for Hydros-
TA vs Synvisc-One were observed at all timepoints over the course of the
study.
The percentage of subjects who responded favorably to the product (as
measured by the OMERACT-OARSI responder rate) was also higher in the
Hydros and Hydros-TA groups when compared to Synvisc-One. Hydros-
TA showed a trend towards a faster onset of pain relief compared to the
non-steroid containing products evaluated in the study. Hydros-TA
provided a 43.5mm mean reduction from baseline pain at the 2 week
time point compared to a mean reduction of 37.7mm and 32.3mm for
Synvisc-One and Hydros, respectively. In the Hydros-TA treatment group
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reports in the Synvisc-One group and 7 events reported in the Hydros
group. Arthralgia was the most commonly reported product-related
adverse event (5 reports with Synvisc-One, 4 with Hydros, and 1 with
Hydros-TA).
Conclusions: A single injection of Hydros or Hydros-TA was well toler-
ated and relieved pain associated with symptomatic OA of the knee over
26 weeks. The study endpoints showed strong trends toward an
enhanced effect compared to Synvisc-One. In fact, in patients with OA
Grade 3, the improvement in pain scores at 2 weeks was signiﬁcantly
greater in the Hydros-TA group compared with the Synvisc-One group.
Future clinical evaluations will be required to further demonstrate the
safety and the superiority of Hydros and Hydros-TA compared to Synvisc-
One.
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AN ORAL PREPARATION CONTAINING HYAL-JOINT DS CAN REDUCE
OSTEOARTHRITIS KNEE PAIN
F. Nelson 1, W.C. Wu 2, R. Zvirbulis 1, B. Zonca 1, M. Pasierb 2,
P. Wilton 3. 1Henry Ford Hosp., Detroit, MI, USA; 2Bone and Joint Ctr., Henry
Ford Hosp., Detroit, MI, USA; 3Wayne State Univeristy Med. Sch., Detroit, MI,
USA
Purpose: This double blind random controlled study was designed to
determine if there is an effect of a speciﬁc oral preparation containing
Hyal-Joint DS on osteoarthritis knee pain.
Methods: 40 symptomatic knee osteoarthritis (OA) patients were
recruited sequentially at the time of an outpatient visit for OA. OA was
documented by either MRI or radiograph. Adult male and female subjects
were between the ages of 50-75 years, had a knee effusion and a pain
visual analog score (VAS) >50mm on a 10 cm line marked by the patient.
Patients were excluded for any inﬂammatory joint disorder such as crys-
talline disease and autoimmune disorders. None had intra-articular
injections such or corticosteroids within 4 weeks or hyaluronic acid within
6 months. Any use of oral corticosteroids within a month or topical
corticosteroids within aweek was excluded. There was no traumawithin 6
months or arthroscopy within 3 months.
After consent was obtained, patients had a knee aspiration and blood
sample saving the ﬂuid for later analysis. To date, 20 have completed. 10
had been randomly selected to receive 80 mg of an oral preparation
(Oralvisc containing Hyal-Joint DS) used daily and the remaining 10 had
identical appearing placebos. High and low VAS pain scores as well as
WOMAC pain scores (0-20) and functional WOMAC scores were recorded
at the ﬁrst and follow-up visits at 4, 8 and 12 weeks. On the ﬁnal visit
a repeat knee aspiration and blood sample was obtained. Age, sex, body
mass index (BMI), activity level, pain medication use, and metabolic
syndrome risk factors were recorded for all patients. For the ﬁrst 20
patients there was no signiﬁcant difference for these measures comparing
active agent and placebo groups.
Results: The initial high VAS and WOMAC pain scores for the treatment
group was 6.700.28 standard error of the mean (SE) and 7.950.81 SE.
For the placebo group these were 5.820.24 SE and 7.201.17 SE. There
was no signiﬁcance difference. There was no statistical difference between
placebo and treatment groups for any of the four visits over the twelve
weeks. However, comparing group VAS high scores the treatment scores
for 8 and 12 weeks were lower with p¼0.086 and 0.63. At 3 months the
WOMAC pain and WOMAC function scores were lower in the treatment
group p¼0.065 and 0.067. The change from the initial high VAS score
within the treatment group to the 8th and 12th week was signiﬁcantly
different p¼0.0140 and 0.0108. The WOMAC pain score was signiﬁcantly
lower at the 12th visit for the treatment group p¼0.0492. There was no
signiﬁcant change in the placebo group or for the WOMAC functional
scores.
Conclusions: The use of Oralvisc, an oral preparation containing Hyal-
Joint DS, has a signiﬁcant impact on knee pain in this group of OA patients.
Speciﬁc inﬂammatory cytokines and chemokines associated with articular
cartilage degradation are being measured and will be compared to the
clinical results in the expanded study of 40 patients.Ă
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THE CHALLENGES OF RECRUITING PATIENTS INTO A SHAM SURGERY
TRIAL
K.B. Hare, S. Lohmander, E.M. Roos. Univ. of Southern Denmark, Odense,
Denmark
Purpose: To examine the feasibility of a randomized placebo (sham)
controlled surgical trial, speciﬁcally to identify the challenges in patient
recruitment. The few available placebo controlled surgical trials and recent
editorials and reviews emphasize that to examine the true efﬁcacy of any
intervention, it needs to be compared against a placebo. We therefore
examined the feasibility of recruiting patients into a placebo controlled
surgical trial of arthroscopic partial meniscectomy.
Methods: Results presented are from an ongoing RCT where patients aged
35-55 with an MRI conﬁrmed degenerative medial meniscus tear were
randomized to arthroscopic partial meniscectomy or placebo surgery. The
placebo surgery consisted of skin incisions made under full anaesthesia at
the medial and lateral portal sites as in a usual arthroscopy. Patients
referred from general practitioners were screened throughout the ortho-
paedic clinics of Region Zealand, Denmark. If eligible, oral and written
information about the study including a 10 minute video was given to the
patients and they were subsequently invited to participate. If willing, they
were referred to an MRI to conﬁrm a meniscus lesion. Only when MRI
conﬁrmed a meniscus lesion were the patients ﬁnally included. Patients
unwilling to participate were asked of reasons why, while ﬁnally included
were asked what mattered most in decision making and which form of
informationwas the most useful. All patients will be seen at 3 months, and
2 and 5 years.
Results: 159 patients have been screened for a medial meniscus tear so far.
Of these patients, 72 had clinical signs of a medial meniscus lesion. 9
patients declined to receive the patient information, 31 declined after
reviewing the patient material and 30 patients agreed to participate (41.6
%). 2 patients underwent MRI which was negative before being informed
of the study. All 30 patients who were willing to participate underwent
MRI. Of these patients, only 12 had a medial meniscus tear conﬁrmed by
MRI (5 pending). In total 10 patients were ﬁnally included from the 159
initially screened. 2 patients who agreed to participate withdrew after
MRI.
8 of the 10 of participating patients weighted the oral information from the
including physician as most important compared to the written informa-
tion and video. The most common reason for participating was the
contribution to science in general and future use for other patients (9/10).
Of the 30 patients who did not wish to participate, after reviewing the
patient information, the reasons were almost equally distributed between;
a) not wanting placebo surgery (29%), b) the risk of undergoing
a secondary operation (22%), and c) not wanting surgery at all but rather
exercise (26%). 10% did not want to participate in any study at all and 13 %
had other reasons.
